|
|
||||||||
|
|
|||||||||
|
|
Radiopharmaceutical Chemistry: New Chemistry-OncologyNew Chemistry-Oncology Posters |
1 Nuclear Medicine, Hamilton Health Sciences, Hamilton, Ontario, Canada; 2 Centre for Gene Therapeutics, McMaster University, Hamilton, Ontario, Canada
1240
Objectives: To investigate the use of [18F]6-fluoro-D-DOPA for the detection of melanoma.
Methods: D- and L- enantiomers of [18F]6-FDOPA were prepared by the direct fluorination of D-and L-DOPA, respectively, in BF3/aHF. B16-F10 melanoma cells (106) grown in complete MEM/F11 medium were tryspsinized and placed on a shaker for six hours to allow re-expression of the surface proteins. They were washed with HBSS buffer and incubated with 500 µCi [18F]6-FDOPA (D- and L-) for 120 min at 37 oC. Cells were centrifuged and washed with HBSS buffer until less than 10% of the total 18F remained in the supernatant. 500 µCi (0.2 mL) of [18F]-labelled D- and L-6FDOPA was injected into the tail veins of B16-F10 melanoma mice after they were anesthetized with isoflurane. PET Images were obtained using a Phillips Mosaic PET scanner and co-registered with CT from a X-SPECT Scanner. Images were reconstructed and time activity curves were obtained for various organs.
Results: 18F uptake in the tumor cells were similar, 20 and 22%, for D- and L- [18F]6-FDOPA, respectively. PET images B16-F10 melanoma mice showed clear delineation of the tumor 120 min after[18F]6-Fluoro-D-DOPA injection. Time activity curves showed slow clearance of 18F from the tumor during the first 45 min and then remained constant.
Conclusions: [18F]-labelled 6-fluoro-D-DOPA is an excellent tracer for the delineation of melanoma. Preliminary results indicate that D-FDOPA behaves like a false precursor of melanin. Use of D-[18F]6-FDOPA would alleviate all problems associated with the formation, in vio, of metabolites from L-[18F]6-FDOPA.
Research Support: We thank Dr. Karen Gulenchyn and Ms. Carol Dunne of HHS for their support.
| ||||||||||||||||||||||||||||||||||||||